Skip to main content

Seasonal Rhinitis and/or Rhinoconjunctivitis

0
Pipeline Programs
2
Companies
6
Clinical Trials
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
0
0
0
0
0
Early DiscoveryClinical DevelopmentMarket

Competitive Landscape

2 companies ranked by most advanced pipeline stage

Hal Allergy
Hal AllergyNetherlands - Leiden
1 program
sublingual immunotherapyPHASE_21 trial
Active Trials
NCT00932607Completed74
Allergy Therapeutics
Allergy TherapeuticsUK - West Sussex
1 program
sublingual immunotherapyPHASE_25 trials
Active Trials
NCT07170540Not Yet Recruiting45Est. Dec 2028
NCT01380327Completed99Est. Jun 2012
NCT01335139Completed106Est. Feb 2015
+2 more trials

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
2027
2028
Allergy Therapeuticssublingual immunotherapy
Allergy Therapeuticssublingual immunotherapy
Hal Allergysublingual immunotherapy
Allergy Therapeuticssublingual immunotherapy
Allergy Therapeuticssublingual immunotherapy
Allergy Therapeuticssublingual immunotherapy

Clinical Trials (6)

Total enrollment: 418 patients across 6 trials

NCT07170540Allergy Therapeuticssublingual immunotherapy

UNC Cashew Sublingual Immunotherapy

Start: Jun 2026Est. completion: Dec 202845 patients
Phase 2Not Yet Recruiting
NCT01335139Allergy Therapeuticssublingual immunotherapy

Long-Term Effects of Sublingual Grass Therapy

Start: Mar 2011Est. completion: Feb 2015106 patients
Phase 2Completed
NCT00932607Hal Allergysublingual immunotherapy

SUBLIVAC® Birch PROBE Study

Start: Jul 200974 patients
Phase 2Completed
NCT01380327Allergy Therapeuticssublingual immunotherapy

Biomarkers of Cockroach Sublingual Immunotherapy 2

Start: May 2011Est. completion: Jun 201299 patients
Phase 1/2Completed
NCT00829985Allergy Therapeuticssublingual immunotherapy

Biomarker-based Cockroach Sublingual Immunotherapy Study (BioCSI)

Start: Jan 2009Est. completion: Dec 200954 patients
Phase 1/2Completed
NCT00580606Allergy Therapeuticssublingual immunotherapy

A Randomized, Double-Blind Placebo-Controlled Peanut Sublingual Immunotherapy Trial

Start: Dec 2007Est. completion: Dec 201440 patients
Phase 1/2Completed

Phase Legend

Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available

Key Insights

2 companies competing in this space

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.